Amneal Targets Limited US Ciprodex Pool With FDA Approval

FDA Approval Marks Another Addition To The Firm’s Growing Complex Drug Portfolio

The FDA has granted approval to Amneal’s ciprofloxacin/dexamethasone otic suspension ANDA product, referencing Ciprodex, adding a further drug to the company’s portfolio as the firm continues its strategic shift to complex generics.

Many hand thumbs up good feedback from business people.
• Source: Shutterstock

More from Products

More from Generics Bulletin